Viridian Therapeutics (VRDN) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 12-month price targets for Viridian Therapeutics' shares. Their VRDN share price forecasts range from $40.00 to $51.00. On average, they predict the company's share price to reach $45.08 in the next year. This suggests a possible upside of 90.0% from the stock's current price.
View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts.

Viridian Therapeutics' stock was trading at $29.21 at the beginning of the year. Since then, VRDN stock has decreased by 18.8% and is now trading at $23.73.
View the best growth stocks for 2023 here.

Viridian Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,360,000 shares, an increase of 24.9% from the April 30th total of 3,490,000 shares. Based on an average daily volume of 604,000 shares, the days-to-cover ratio is currently 7.2 days.
View Viridian Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VRDN earnings forecast.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its earnings results on Tuesday, May, 9th. The company reported ($1.61) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by $0.61. The business earned $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Viridian Therapeutics had a negative net margin of 10,419.10% and a negative trailing twelve-month return on equity of 89.08%. The company's revenue for the quarter was down 54.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share.

ETFs with the largest weight of Viridian Therapeutics (NASDAQ:VRDN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC).BlackRock Future Health ETF (BMED) and

Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN."

Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.43%), State Street Corp (5.57%), Commodore Capital LP (5.08%), Perceptive Advisors LLC (4.03%), Pictet Asset Management SA (2.42%) and Logos Global Management LP (2.20%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers.
View institutional ownership trends.

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRDN stock can currently be purchased for approximately $23.73.

Viridian Therapeutics (NASDAQ:VRDN) has a market capitalization of $1.02 billion and generates $1.77 million in revenue each year. The company earns $-129,870,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

Viridian Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.viridiantherapeutics.com. The company can be reached via phone at (617) 272-4600, via email at daniel@lifesciadvisors.com, or via fax at 760-537-4101.